Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform
Developing Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform
Developing Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects